AL AMYLOIDOSIS
Clinical trials for AL AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AL AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AL AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat amyloidosis patients with prior drug exposure
Disease control OngoingThis study tests whether adding daratumumab to pomalidomide and dexamethasone can improve complete remission rates in people with light chain amyloidosis whose disease has returned or not responded after prior daratumumab treatment. About 15 adults with measurable disease who hav…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated May 26, 2026 06:10 UTC
-
New hope: drug may delay relapse in rare amyloidosis
Disease control OngoingThis study tests whether the chemotherapy drug Ixazomib can help control AL amyloidosis, a rare disease where abnormal proteins build up in organs. Seventeen adults who completed initial therapy receive Ixazomib as maintenance to prevent or delay relapse. The goal is to see if th…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 06:03 UTC
-
New drug cocktail targets Hard-to-Treat amyloidosis in early trial
Disease control OngoingThis early-stage trial is testing a combination of three drugs (venetoclax, ixazomib, and dexamethasone) in 24 people with a rare blood disease called light chain amyloidosis that has returned or not responded to prior treatments. The study only includes patients with a specific …
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New antibody aims to clear toxic proteins from organs in rare disease
Disease control OngoingThis study tests an experimental drug called CAEL-101 in people with AL amyloidosis, a rare disease where abnormal proteins build up in organs like the heart and kidneys. The drug is designed to remove these protein deposits. About 281 participants will receive either CAEL-101 or…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New Slow-Go drug shows promise for rare blood disease
Disease control OngoingThis early-phase trial tests a drug called isatuximab in 11 people with a rare, high-risk blood disease called AL amyloidosis. The goal is to see if a slower, gentler treatment approach can control the disease with fewer side effects. Isatuximab is an antibody that helps stop abn…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New antibody could extend life for patients with rare, fatal amyloidosis
Disease control OngoingThis study tests an experimental drug called CAEL-101 in people with a rare disease called AL amyloidosis, where abnormal proteins build up in organs like the heart and kidneys. The drug aims to remove these protein deposits to help patients live longer and avoid heart-related ho…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug aims to reduce post-transplant misery for older cancer patients
Symptom relief OngoingThis study tests whether a drug called siltuximab can reduce symptoms like fatigue, pain, and nausea after a stem cell transplant. It includes 30 patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein linked to inflammation, which may help patients…
Matched conditions: AL AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated May 26, 2026 06:03 UTC